Ulster University Logo

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.

Irwin, Nigel and Flatt, Peter (2013) Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Current Opinion in Pharmacology, 13 (6). pp. 989-995. [Journal article]

Full text not available from this repository.

DOI: 10.1016/j.coph.2013.09.009

Abstract

The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences > School of Biomedical Sciences
Faculty of Life and Health Sciences > School of Pharmacy and Pharmaceutical Science
Faculty of Life and Health Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
ID Code:27404
Deposited By: Dr Nigel Irwin
Deposited On:08 Oct 2013 08:42
Last Modified:15 Apr 2014 14:08

Repository Staff Only: item control page